The evolving challenge of therapy-related myeloid neoplasms

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 4, 2013, Pages 309-317

  Churpek, Jane E ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

leukemia; myelodysplastic syndrome; myeloid; neoplasm; therapy related

Indexed keywords

AZATHIOPRINE; CHLORMETHINE; CYTARABINE; GLUTATHIONE TRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; HEMOPOIETIC GROWTH FACTOR; LACTATE DEHYDROGENASE; MELPHALAN; PROCARBAZINE; REACTIVE OXYGEN METABOLITE;

ALGORITHM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TUMOR; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CELL DIVISION; CHEMORADIOTHERAPY; CHROMOSOME BAND; CLINICAL FEATURE; CYTOGENETICS; DNA DAMAGE; DNA REPAIR; DRUG METABOLISM; DYSKERATOSIS CONGENITA; FAMILIAL CANCER; FANCONI ANEMIA; FATIGUE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; MALAISE; MEGALOCYTOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PETECHIA; PHYSICAL EXAMINATION; POPULATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK FACTOR; SOLID TUMOR; THERAPY RELATED MYELODYSPLASTIC NEOPLASM; TREATMENT OUTCOME;

LEUKEMIA; MYELODYSPLASTIC SYNDROME; MYELOID; NEOPLASM; THERAPY-RELATED;

DNA DAMAGE; DNA REPAIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY;

EID: 84893816646     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.09.001     Document Type: Review

References (35)

1. J.W. Vardiman, D.A. Arber, and R.D. Brunning et al. Classification of tumours of haematopoietic and lymphoid tissues 4th ed. 2008 IARC Press Lyon, France 127 129
2. S. Kayser, K. Dohner, and J. Krauter et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML Blood 117 7 2011 2137 2145
3. S.M. Smith, M.M. Le Beau, and D. Huo et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series Blood 102 1 2003 43 52
4. K. Takeyama, M. Seto, and N. Uike et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors Int J Hematol 71 2 2000 144 152
5. L.A. Godley, and R.A. Larson Therapy-related myeloid leukemia Semin Oncol 35 4 2008 418 429
6. R.A. Larson Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms J Clin Oncol 30 19 2012 2300 2302
7. A.M. Pascual, N. Tellez, and I. Bosca et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required Mult Scler 15 11 2009 1303 1310
8. R. Siegel, C. DeSantis, and K. Virgo et al. Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 4 2012 220 241
9. M.C. Le Deley, F. Suzan, and B. Cutuli et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer J Clin Oncol 25 3 2007 292 300
10. R.E. Smith, J. Bryant, and A. DeCillis et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience J Clin Oncol 21 7 2003 1195 1204
11. R.H. Advani, R.T. Hoppe, and S.A. Rosenberg et al. Incidence of secondary leukemia/myelodysplasia in Hodgkin's disease with three generations of therapy at Stanford University ASCO 2006 Proceedings J Clin Oncol 24 18S 2006 Abstract #7516
12. E. Brusamolino, A. Baio, and E. Orlandi et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up Clin Cancer Res 12 21 2006 6487 6493
13. E. Brusamolino, M. Gotti, and V. Fiaccadori The risk of therapy-related myelodysplasia/acute myeloid leukemia in Hodgkin lymphoma has substantially decreased in the ABVD era abolishing mechlorethamine and procarbazine and limiting volumes and doses of radiotherapy Med J Hematol Infect Dis 4 1 2012 e2012022
14. V. Delwail, J.P. Jais, and P. Colonna et al. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation Br J Haematol 118 1 2002 189 194
15. E. Brusamolino, A.P. Anselmo, and C. Klersy et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study Haematologica 83 9 1998 812 823
16. G.H. Lyman, D.C. Dale, and D.A. Wolff et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review J Clin Oncol 28 17 2010 2914 2924
17. R.A. Larson, Y. Wang, and M. Banerjee et al. Prevalence of the inactivating 609C - >T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia Blood 94 2 1999 803 807
18. J.M. Allan, C.P. Wild, and S. Rollinson et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia Proc Natl Acad Sci U S A 98 20 2001 11592 11597
19. N.A. Ellis, D. Huo, and O. Yildiz et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility Blood 112 3 2008 741 749
20. P.S. Rosenberg, M.H. Greene, and B.P. Alter Cancer incidence in persons with Fanconi anemia Blood 101 3 2003 822 826
21. B.P. Alter, N. Giri, and S.A. Savage et al. Cancer in dyskeratosis congenita Blood 113 26 2009 6549 6557
22. D.C. Link, L.G. Schuettpelz, and D. Shen et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML J Am Med Assoc 305 15 2011 1568 1576
23. M.G. Martin, M. Jacoby, and J. Shao et al. BRCA1 and BRCA2 Nucleotide variants in Young Women with therapy related acute myeloid leukemias Blood 114 2009 Abstract 1102
24. E. Schulz, A. Valentin, and P. Ulz et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms J Med Genet 49 7 2012 422 428
25. H. Dohner, E.H. Estey, and S. Amadori et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 3 2010 453 474
26. C. Schoch, W. Kern, and S. Schnittger et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML Leukemia 18 1 2004 120 125
27. B. Quesnel, H. Kantarjian, and J.P. Bjergaard et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature J Clin Oncol 11 12 1993 2370 2379
28. M. Beaumont, M. Sanz, and P.M. Carli et al. Therapy-related acute promyelocytic leukemia J Clin Oncol 21 11 2003 2123 2137
29. A. Pulsoni, L. Pagano, and F. Lo Coco et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience Blood 100 6 2002 1972 1976
30. F. Ravandi Therapy-related acute promyelocytic leukemia Haematologica 96 4 2011 493 495
31. F. Lo Coco, G. Avvisati, and S.M. Orlando et al. ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic leukemia: results of the phase III, prospective, randomized, intergroup APL0406 study by the Italian-German cooperative groups GIMEMA-SAL-AMLSG Blood 120 2012 6 Abstract #6
32. J.E. Anderson, T.A. Gooley, and G. Schoch et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy Blood 89 7 1997 2578 2585
33. M.R. Litzow, S. Tarima, and W.S. Perez et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia Blood 115 9 2010 1850 1857
34. I. Yakoub-Agha, P. de La Salmoniere, and P. Ribaud et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation J Clin Oncol 18 5 2000 963 971
35. W. Zinke-Cerwenka, A. Valentin, and U. Posch et al. Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies Bone Marrow Transplant 46 12 2011 1540 1544